Questions • challenges • controversies: How clinically relevant is dapsone-related peripheral neuropathy? An overview of available data with emphasis on clinical recognition

Journal of Clinical and Aesthetic Dermatology

Volumn 3, Issue 3, 2010, Pages

  McCarty, Morgan ^a   del Rosso, James Q ^b  

^a MIDWESTERN UNIVERSITY   (United States)

^b VALLEY HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIMETIDINE; DAPSONE;

ACETYLATOR PHENOTYPE; ACNE CONGLOBATA; AGRANULOCYTOSIS; ARTICLE; BEHCET DISEASE; DERMATITIS HERPETIFORMIS; DRUG ACCUMULATION; DRUG INDUCED DISEASE; ELECTROMYOGRAPHY; ERYTHEMA; ERYTHEMA ELEVATUM DIUTINUM; FUNCTION TEST; GAIT; GAIT DISORDER; HEMOLYTIC ANEMIA; HUMAN; INFECTION; LEPROSY; LEUCOCYTOCKASTIC VASCULITIS; METHEMOGLOBINEMIA; MOTOR DYSFUNCTION; MOTOR NEUROPATHY; MUSCLE ATROPHY; MUSCLE STRENGTH; NEUROTOXICITY; OPTIC NERVE DISEASE; PATIENT EDUCATION; PEMPHIGOID; PEMPHIGUS; PERIPHERAL NEUROPATHY; PERONEUS NERVE PARALYSIS; PHYSICAL EXAMINATION; PNEUMOCYSTIS PNEUMONIA; POLYCHONDRITIS; REMISSION; RISK ASSESSMENT; SENSORY NEUROPATHY; SKIN DISEASE; SYMPTOMATOLOGY; TREATMENT DURATION; VASCULITIS;

EID: 77954282858     PISSN: 19412789     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Wolf R, Matz R, Orion E, Tuzun B, Tuzun Y. Dapsone. Dermatol Online J. 2002;8(1):2.
2. Coleman M. Review dapsone: modes of action, toxicity and possible strategies for increasing patient tolerance. Br J Dermatol. 1993;129:507-513.
3. Golusin Z, Poljacki M, Preveden R, Stojanoviç S, Rajiç N. What do we know today about diamino-diphenylsulfone? Med Pregl. 2000; 53(7-8):369-372.
4. Ahrens E, Meckler R, Callen J. Dapsone-induced peripheral neuropathy. Int J Dermatol. 1986;25(5): 314-316.
5. Rhodes L, Coleman M, Lewis-Jones M. Dapsone-induced motor peripheral neuropathy in pemphigus foliaceus. Clin Exp Dermatol. 1995;20:155-156.
6. Gurcan H, Ahmed A. Efficacy of dapsone in the treatment of pemphigus and pemphigoid. Am J Clin Dermatol. 2009; 10(6): 383-396.
7. Helweg-Larsen J, Benfield T, Atzori C, Miller R. Clinical efficacy of firstand second-line treatments for HIV-associated Pneumocystis jirovecii pneumonia: a tri-centre cohort study. J Antimicrob Chemother. 2009;64(6):1282-1290.
8. Chalioulias K, Mayer E, Darvay A, Antcliff R. Anterior ischemic optic neuropathy associated with dapsone. Eye. 2006;20:943-945.
9. Saqueton A, Lorinez A, Vick N, et al. Dapsone and peripheral motor neuropathy. Arch Dermatol. 1969;100:214-217.
10. Craig A, Richardson J. Acquired peripheral neuropathy. Phys Med Rehabil Clin N Am. 2003;14 (2):365-386.
11. Coleman M, Rhodes L, Scott et al. The use of cimetidine to reduce dapsone-dependent methaemo-globinacmia in dermatitis herpeti-formis patients. Br J Clin Pharmacol. 1992;34:244.
12. May D, Porter J, Uetrecht J et al. The contribution of N-hydroxyiation and acetyiation to dapsone pharmaco-kinetics in normal subjects. Clin Pharmacol Ther. 1990;48:619-627.